



THE WHITE HOUSE
WASHINGTON

COVID-19 Press Briefing

June 17, 2021



FOR IMMEDIATE RELEASE

June 17, 2021

Biden Administration to Invest \$3.2 Billion from American Rescue Plan as Part of COVID-19 Antiviral Development Strategy

Whole-of-Government Effort Will Develop Next Generation of COVID-19 Treatments, Better Prepare U.S. to Respond to Future Virus Threats







**The Antiviral Program for
Pandemics (APP) aims to
catalyze the development of new
medicines to combat COVID-19
and prepare for other pandemic
threats**



Few Treatments Exist for Many Viruses with Pandemic Potential



Coronaviridae
e.g., SARS, MERS




Bunyaviridae
e.g., Hemorrhagic fevers, Hantavirus, Lassa fever



Filoviridae
e.g., Ebola, Marburg




Flaviviridae
e.g., West Nile, Dengue



Paramyxoviridae
e.g., Nipah, RSV



Picornaviridae
e.g., Enterovirus D68



Togaviridae
e.g., Chikungunya

Rationale and Goals for the Antiviral Program for Pandemics

- Vaccines remain the centerpiece of our arsenal against COVID-19
- Antivirals can be an important complement to existing vaccines and medicines, especially for:
 - Individuals with certain conditions for whom vaccines may not be as protective
 - Adding a line of defense against emerging variants of concern



- APP will bring together leading scientists from academia and industry to accelerate the discovery and development of new antivirals
- In addition to SARS-CoV-2, the program will target other viruses of pandemic potential



APP Will Utilize a Two-Pronged Approach for New Medicines Against Viruses of Pandemic Potential



Discovery

- Expand basic science knowledge and discover new antiviral medicines



Development

- Accelerate clinical testing of promising antiviral medicines

Antiviral Program for Pandemics

Total = \$3.2 billion

- **\$500 million for research and laboratory support**
- **\$1 billion for preclinical and clinical evaluation**
- **\$700 million for development and manufacturing through NIH and BARDA**
- **\$1 billion to support the creation of collaborative drug discovery groups called Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern**



Next Steps

- **Continue engagement with manufacturers to accelerate testing and authorization of promising antiviral medicines in late-stage development**
- **Continue to identify and evaluate additional drug candidates for program support**
- **Support academic-industry partnerships aimed at discovering new molecules**



Daily Change in COVID-19 Cases, US

January 22, 2020 – June 15, 2021

TOTAL Cases Reported Since 1/22/20

33,315,272

NEW Cases Reported to CDC on 6/15/21

12,322

Change in 7-Day Case Average


-15.8%

Current 7-Day Case Average (6/9/21 - 6/15/21)

12,192

Prior 7-Day Case Average (6/2/21 - 6/8/21)

14,472



New Admissions of Patients with Confirmed COVID-19, US

August 1, 2020 – June 14, 2021

Patients Currently Hospitalized with COVID on 6/14/21

13,245

New Admissions on 6/14/21

1,760

Peak in New Admissions (1/5/21)

17,963

Change in 7-Day Average of New Admissions


-9.8%

Current 7-Day Average of New Admissions (6/8/21 - 6/14/21)

2,027

Prior 7-Day Average of New Admissions (6/1/21 - 6/7/21)

2,248



Daily Change in COVID-19 Deaths, US

January 22, 2020 – June 15, 2021

TOTAL Deaths Reported Since 1/22/2020

597,965

NEW Deaths Reported to CDC on 6/15/21

373

Change in 7-Day Death Average

-24.8%

Current 7-Day Death Average (6/9/21 - 6/15/21)


286

Prior 7-Day Death Average (6/2/21 - 6/8/21)

380

Forecasted Total Deaths by 7/10/21

604,000 to 613,000





THE WHITE HOUSE
WASHINGTON

WH.GOV